Paul Decker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Paul Decker has a total of 184 co-authors. Here are the top co-authors by number of shared publications:
Roland Jaussaud
Département de Médecine Interne et Immunologie Clinique, CHRU Nancy, Vandœuvre-lès-Nancy, France; EA 3450 DevAH - Développement, Adaptation et Handicap, Université de Lorraine, Vandœuvre-lès-Nancy, France
9 shared publicationsThomas Moulinet
Département de Médecine Interne et Immunologie Clinique, CHRU Nancy, Vandœuvre-lès-Nancy, France; UMR 7365 CNRS-Université de Lorraine IMoPA, Université de Lorraine, Vandœuvre-lès-Nancy, France
7 shared publications- Thomas Moulinet
Department of Internal Medicine and clinical immunology, CHRU Nancy , Nancy
5 shared publications Bernard Bonnotte
Département de Médecine Interne et Immunologie Clinique, CHU Dijon, Dijon, France
4 shared publicationsJulien Campagne
Service de Médecine Interne, Uneos, Metz, France
4 shared publicationsAlain Meyer
Département de Rhumatologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
3 shared publications
Latest Publications
- Open Access
- 4 June 2026
- Published by Elsevier in Archivos de Bronconeumología
- Vol. 62 (11) , 780-788
Longitudinal Trajectories of Antisynthetase Syndrome-associated Interstitial Lung Disease
- 4 June 2026
- Published by Elsevier in Archivos de Bronconeumología
- Vol. 62 (11) , 780-788
Open AccessLongitudinal Trajectories of Antisynthetase Syndrome-associated Interstitial Lung Disease
- 17 April 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (5)
Spectrum and significance of 18F-FDG-PET/CT abnormalities in VEXAS syndrome
Objective: VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) is a recently identified adult-onset autoinflammatory disorder caused by somatic mutations in UBA1. It is characterized by heterogeneous inflammatory and haematological manifestations, making diagnosis challenging. 18F-FDG-PET/CT imaging, which identifies metabolic activity associated with inflammation and malignancy, is often performed during the diagnostic work-up. However, its utility in VEXAS syndrome remains unclear. Methods: We conducted a multicentre retrospective observational study of patients with genetically-confirmed VEXAS syndrome who underwent 18F-FDG-PET/CT imaging. Clinical, laboratory and imaging data were collected, and 18F-FDG-PET/CT findings were analysed according to disease activity, myelodysplastic syndrome status and mortality. Qualitative 18F-FDG-PET/CT interpretations were based on local nuclear medicine reports. Results: A total of 125 18F-FDG-PET/CT scans were analysed in 66 patients. Bone marrow (83%) and lymph nodes (53%) were the most frequent sites of abnormal FDG uptake, with combinations of bone marrow, lungs, lymph nodes and spleen being the most common patterns. Pulmonary (38%) and vascular involvement (11%) were also observed. The number of organs with abnormal FDG uptake was significantly higher in patients with active disease compared with remission (median 2 vs 1 abnormal sites, P < 0.001). However, 90% of scans performed during presumed clinical remission showed persistent abnormalities, especially in the bone marrow (57%). Conclusion: 18F-FDG-PET/CT imaging reveals frequent but non-specific abnormalities in VEXAS syndrome, with persistent bone marrow hypermetabolism suggesting subclinical disease activity. While 18F-FDG-PET/CT may have limited diagnostic utility, it holds potential for disease monitoring.
- 17 April 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (5)
Spectrum and significance of 18F-FDG-PET/CT abnormalities in VEXAS syndrome
Objective: VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) is a recently identified adult-onset autoinflammatory disorder caused by somatic mutations in UBA1. It is characterized by heterogeneous inflammatory and haematological manifestations, making diagnosis challenging. 18F-FDG-PET/CT imaging, which identifies metabolic activity associated with inflammation and malignancy, is often performed during the diagnostic work-up. However, its utility in VEXAS syndrome remains unclear. Methods: We conducted a multicentre retrospective observational study of patients with genetically-confirmed VEXAS syndrome who underwent 18F-FDG-PET/CT imaging. Clinical, laboratory and imaging data were collected, and 18F-FDG-PET/CT findings were analysed according to disease activity, myelodysplastic syndrome status and mortality. Qualitative 18F-FDG-PET/CT interpretations were based on local nuclear medicine reports. Results: A total of 125 18F-FDG-PET/CT scans were analysed in 66 patients. Bone marrow (83%) and lymph nodes (53%) were the most frequent sites of abnormal FDG uptake, with combinations of bone marrow, lungs, lymph nodes and spleen being the most common patterns. Pulmonary (38%) and vascular involvement (11%) were also observed. The number of organs with abnormal FDG uptake was significantly higher in patients with active disease compared with remission (median 2 vs 1 abnormal sites, P < 0.001). However, 90% of scans performed during presumed clinical remission showed persistent abnormalities, especially in the bone marrow (57%). Conclusion: 18F-FDG-PET/CT imaging reveals frequent but non-specific abnormalities in VEXAS syndrome, with persistent bone marrow hypermetabolism suggesting subclinical disease activity. While 18F-FDG-PET/CT may have limited diagnostic utility, it holds potential for disease monitoring.
- 29 January 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (2)
Comparison of disease severity and activity between juvenile- and adult-onset dermatomyositis: a multicentre cohort study
Objectives: To compare the severity at diagnosis and disease activity during follow-up between juvenile (jDM) and adult-onset (aDM) dermatomyositis. Methods: Patients with DM fulfilling the 2017 ACR/EULAR criteria and tested for myositis-specific antibodies were included. Overall severity at diagnosis was defined by at least one of the following: severe muscle impairment, symptomatic interstitial lung disease (ILD), gastrointestinal (GI) vasculitis, myocarditis, severe skin ulceration or admission to an intensive care unit. Clinically inactive disease and remission were defined according to PRINTO group criteria and IMACS guidelines. Results: Two hundred and one patients were included: 123 with aDM (≥18 years) and 78 with jDM (<18 years). Female predominance was less pronounced and GI involvement was more frequent in jDM. Anti-nuclear matrix protein 2 (NXP2) antibodies (Abs) were more frequent in jDM. Severe disease at diagnosis was present in 44% of cases, with symptomatic ILD more common in adults and GI vasculitis more common in children. No difference was observed in severe muscle disease. In jDM, anti-NXP2 Abs (odds ratio [OR] = 6.29 [2.00, 23.07], P = 0.003) and joint involvement (OR = 3.44 [1.33, 11.47], P = 0.03) were associated with severe disease at diagnosis, while in aDM, anti-Mi2 Abs were associated with a lower likelihood of severe disease (OR = 0.12 [0.02, 0.42], P = 0.003). No significant difference was observed in clinically inactive disease or remission at the last follow-up. Severe infections occurred in 25% of patients. Conclusion: Severity profiles differ by age of DM onset. Autoantibodies are key indicators of severity at diagnosis in both juvenile DM and adult DM.
- 29 January 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (2)
Comparison of disease severity and activity between juvenile- and adult-onset dermatomyositis: a multicentre cohort study
Objectives: To compare the severity at diagnosis and disease activity during follow-up between juvenile (jDM) and adult-onset (aDM) dermatomyositis. Methods: Patients with DM fulfilling the 2017 ACR/EULAR criteria and tested for myositis-specific antibodies were included. Overall severity at diagnosis was defined by at least one of the following: severe muscle impairment, symptomatic interstitial lung disease (ILD), gastrointestinal (GI) vasculitis, myocarditis, severe skin ulceration or admission to an intensive care unit. Clinically inactive disease and remission were defined according to PRINTO group criteria and IMACS guidelines. Results: Two hundred and one patients were included: 123 with aDM (≥18 years) and 78 with jDM (<18 years). Female predominance was less pronounced and GI involvement was more frequent in jDM. Anti-nuclear matrix protein 2 (NXP2) antibodies (Abs) were more frequent in jDM. Severe disease at diagnosis was present in 44% of cases, with symptomatic ILD more common in adults and GI vasculitis more common in children. No difference was observed in severe muscle disease. In jDM, anti-NXP2 Abs (odds ratio [OR] = 6.29 [2.00, 23.07], P = 0.003) and joint involvement (OR = 3.44 [1.33, 11.47], P = 0.03) were associated with severe disease at diagnosis, while in aDM, anti-Mi2 Abs were associated with a lower likelihood of severe disease (OR = 0.12 [0.02, 0.42], P = 0.003). No significant difference was observed in clinically inactive disease or remission at the last follow-up. Severe infections occurred in 25% of patients. Conclusion: Severity profiles differ by age of DM onset. Autoantibodies are key indicators of severity at diagnosis in both juvenile DM and adult DM.
- Open Access
- 10 December 2025
- Published by Wiley in Journal of Internal Medicine
- Vol. 299 (3) , 365-380
Clinical profiles associated with rapidly progressive interstitial lung disease in antisynthetase syndrome: A multicentric cohort study (TYPASS study)
Objectives: To assess factors associated with rapidly progressive interstitial lung disease (ILD) (RP‐ILD) at time of ILD diagnosis in a multicentric retrospective cohort study of antisynthetase syndrome (ASyS). We used a complementary unsupervised approach, hierarchical clustering, to delineate distinct phenotypes among ASyS patients with ILD. Methods: A total of 132 patients with ASyS, defined according to the 2024 ACR/European Alliance of Associations for Rheumatology (EULAR) ASyS classification criteria, and ILD, diagnosed by CT scan, were included. RP‐ILD was defined by the presence of respiratory failure at ILD diagnosis or rapid ILD progression during the first 3 months. Results: In our study, 39% of patients had RP‐ILD at ILD diagnosis. Multivariate logistic regression analysis with cluster‐robust SE identified the factors associated with RP‐ILD at ILD diagnosis as male sex (aOR = 9.7 [1.6–59.5], p = 0.006), fever (aOR = 128 [12.6–1300], p < 0.001), organizing pneumonia (OP) pattern (aOR = 66.8 [3.4–1316], p = 0.006), and pleural effusion (aOR = 20.2 [1.1–373], p = 0.04), whereas RP‐ILD was associated with lower likelihood of severe muscle disease (aOR = 0.004 [0.0001–0.13], p = 0.002). Clustering analysis identified four distinct groups: Cluster 1 ( n = 62) included patients with systemic presentation, non‐RP‐ILD at ILD diagnosis, and anti‐Jo‐1 antibodies with good prognosis; Cluster 2 ( n = 40) included older age patients with more RP‐ILD at ILD diagnosis, pleuropericarditis, and a higher mortality rate. Conclusion: Fever, pleural effusion, and OP pattern were independently associated with RP‐ILD in ASyS patients. Unsupervised cluster analysis identified a severe inflammatory phenotype in ASyS patients with ILD.
- 10 December 2025
- Published by Wiley in Journal of Internal Medicine
- Vol. 299 (3) , 365-380
Open AccessClinical profiles associated with rapidly progressive interstitial lung disease in antisynthetase syndrome: A multicentric cohort study (TYPASS study)
Objectives: To assess factors associated with rapidly progressive interstitial lung disease (ILD) (RP‐ILD) at time of ILD diagnosis in a multicentric retrospective cohort study of antisynthetase syndrome (ASyS). We used a complementary unsupervised approach, hierarchical clustering, to delineate distinct phenotypes among ASyS patients with ILD. Methods: A total of 132 patients with ASyS, defined according to the 2024 ACR/European Alliance of Associations for Rheumatology (EULAR) ASyS classification criteria, and ILD, diagnosed by CT scan, were included. RP‐ILD was defined by the presence of respiratory failure at ILD diagnosis or rapid ILD progression during the first 3 months. Results: In our study, 39% of patients had RP‐ILD at ILD diagnosis. Multivariate logistic regression analysis with cluster‐robust SE identified the factors associated with RP‐ILD at ILD diagnosis as male sex (aOR = 9.7 [1.6–59.5], p = 0.006), fever (aOR = 128 [12.6–1300], p < 0.001), organizing pneumonia (OP) pattern (aOR = 66.8 [3.4–1316], p = 0.006), and pleural effusion (aOR = 20.2 [1.1–373], p = 0.04), whereas RP‐ILD was associated with lower likelihood of severe muscle disease (aOR = 0.004 [0.0001–0.13], p = 0.002). Clustering analysis identified four distinct groups: Cluster 1 ( n = 62) included patients with systemic presentation, non‐RP‐ILD at ILD diagnosis, and anti‐Jo‐1 antibodies with good prognosis; Cluster 2 ( n = 40) included older age patients with more RP‐ILD at ILD diagnosis, pleuropericarditis, and a higher mortality rate. Conclusion: Fever, pleural effusion, and OP pattern were independently associated with RP‐ILD in ASyS patients. Unsupervised cluster analysis identified a severe inflammatory phenotype in ASyS patients with ILD.
- 15 July 2024
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (4) , 2209-2213
Long-term outcomes of childhood-onset systemic lupus erythematosus
Data on the long-term outcome of patients with childhood-onset SLE (cSLE) are scarce. Aims of this study were to describe the long-term outcomes of cSLE and to identify factors associated with the development of damage and persistent disease activity. We conducted a retrospective multicentre study using data from the PEDIALUP registry of the Juvenile Inflammatory Rheumatism (JIR) cohort database. Demographic characteristics, clinical manifestations, laboratory, radiological, histological and treatment data were collected from medical records during follow-up. A total of 138 patients with cSLE, diagnosed between 1971 and 2015, were included. With a median follow-up of 15.4 [9.6–22.4] years, 51% of patients had a SLICC-damage index (DI) score ≥1 at last follow-up with the musculoskeletal, cutaneous, renal, neurological and cardiovascular damage being the most common manifestations. The proportion of patients with a SLICC-DI score ≥1 increased significantly with the duration of the follow-up (P < 0.001). On multivariate analysis, duration of follow-up was associated with increased risk of cumulative damage (OR 1.08, 95% CI 1.01, 1.15, P = 0.035). At the last visit, 34% of patients still had active disease with a SLEDAI score of ≥6. On multivariate analysis, sub-Saharan African ethnicity was associated with 7-fold increased odds of having active disease at the last visit compared with Caucasians (OR 7.44, 95% CI 2.24, 24.74, P = 0.0002). The prevalence of damage remains high in patients with cSLE even when the diagnosis of cSLE has been made in the recent decades.
- 15 July 2024
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (4) , 2209-2213
Long-term outcomes of childhood-onset systemic lupus erythematosus
Data on the long-term outcome of patients with childhood-onset SLE (cSLE) are scarce. Aims of this study were to describe the long-term outcomes of cSLE and to identify factors associated with the development of damage and persistent disease activity. We conducted a retrospective multicentre study using data from the PEDIALUP registry of the Juvenile Inflammatory Rheumatism (JIR) cohort database. Demographic characteristics, clinical manifestations, laboratory, radiological, histological and treatment data were collected from medical records during follow-up. A total of 138 patients with cSLE, diagnosed between 1971 and 2015, were included. With a median follow-up of 15.4 [9.6–22.4] years, 51% of patients had a SLICC-damage index (DI) score ≥1 at last follow-up with the musculoskeletal, cutaneous, renal, neurological and cardiovascular damage being the most common manifestations. The proportion of patients with a SLICC-DI score ≥1 increased significantly with the duration of the follow-up (P < 0.001). On multivariate analysis, duration of follow-up was associated with increased risk of cumulative damage (OR 1.08, 95% CI 1.01, 1.15, P = 0.035). At the last visit, 34% of patients still had active disease with a SLEDAI score of ≥6. On multivariate analysis, sub-Saharan African ethnicity was associated with 7-fold increased odds of having active disease at the last visit compared with Caucasians (OR 7.44, 95% CI 2.24, 24.74, P = 0.0002). The prevalence of damage remains high in patients with cSLE even when the diagnosis of cSLE has been made in the recent decades.
- Top Cited Papers
- 22 May 2024
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 83 (10) , 1358-1367
Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX
Objectives Vacuoles, E1 enzyme, X-linked, autoinflammatory and somatic (VEXAS) syndrome is an adult-onset autoinflammatory disease associated with somatic ubiquitin-like modifier-activating enzyme 1 (UBA1) mutations. We aimed to evaluate the efficacy and safety of targeted therapies. Methods Multicentre retrospective study including patients with genetically proven VEXAS syndrome who had received at least one targeted therapy. Complete response (CR) was defined by a clinical remission, C-reactive protein (CRP) ≤10 mg/L and a ≤10 mg/day of prednisone-equivalent therapy, and partial response (PR) was defined by a clinical remission and a 50% reduction in CRP levels and glucocorticoid dose. Results 110 patients (median age 71 (68–79) years) who received 194 targeted therapies were included: 78 (40%) received Janus kinase (JAK) inhibitors (JAKi), 51 (26%) interleukin (IL)-6 inhibitors, 33 (17%) IL-1 inhibitors, 20 (10%) tumour necrosis factor (TNFα) blockers and 12 (6%) other targeted therapies. At 3 months, the overall response (CR and PR) rate was 24% with JAKi, 32% with IL-6 inhibitors, 9% with anti-IL-1 and 0% with TNFα blockers or other targeted therapies. At 6 months, the overall response rate was 30% with JAKi and 26% with IL-6 inhibitors. Survival without treatment discontinuation was significantly longer with JAKi than with the other targeted therapies. Among patients who discontinued treatment, causes were primary failure, secondary failure, serious adverse event or death in 43%, 14%, 19% and 19%, respectively, with JAKi and 46%, 11%, 31% and 9%, respectively, with IL-6 inhibitors. Conclusions This study shows the benefit of JAKi and IL-6 inhibitors, whereas other therapies have lower efficacy. These results need to be confirmed in prospective trials.
- 22 May 2024
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 83 (10) , 1358-1367
Top Cited PapersEfficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX
Objectives Vacuoles, E1 enzyme, X-linked, autoinflammatory and somatic (VEXAS) syndrome is an adult-onset autoinflammatory disease associated with somatic ubiquitin-like modifier-activating enzyme 1 (UBA1) mutations. We aimed to evaluate the efficacy and safety of targeted therapies. Methods Multicentre retrospective study including patients with genetically proven VEXAS syndrome who had received at least one targeted therapy. Complete response (CR) was defined by a clinical remission, C-reactive protein (CRP) ≤10 mg/L and a ≤10 mg/day of prednisone-equivalent therapy, and partial response (PR) was defined by a clinical remission and a 50% reduction in CRP levels and glucocorticoid dose. Results 110 patients (median age 71 (68–79) years) who received 194 targeted therapies were included: 78 (40%) received Janus kinase (JAK) inhibitors (JAKi), 51 (26%) interleukin (IL)-6 inhibitors, 33 (17%) IL-1 inhibitors, 20 (10%) tumour necrosis factor (TNFα) blockers and 12 (6%) other targeted therapies. At 3 months, the overall response (CR and PR) rate was 24% with JAKi, 32% with IL-6 inhibitors, 9% with anti-IL-1 and 0% with TNFα blockers or other targeted therapies. At 6 months, the overall response rate was 30% with JAKi and 26% with IL-6 inhibitors. Survival without treatment discontinuation was significantly longer with JAKi than with the other targeted therapies. Among patients who discontinued treatment, causes were primary failure, secondary failure, serious adverse event or death in 43%, 14%, 19% and 19%, respectively, with JAKi and 46%, 11%, 31% and 9%, respectively, with IL-6 inhibitors. Conclusions This study shows the benefit of JAKi and IL-6 inhibitors, whereas other therapies have lower efficacy. These results need to be confirmed in prospective trials.
- 9 December 2023
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 83 (3) , 372-381
Serious infections in patients with VEXAS syndrome: data from the French VEXAS registry
Introduction Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is an acquired autoinflammatory monogenic disease with a poor prognosis whose determinants are not well understood. We aimed to describe serious infectious complications and their potential risk factors. Methods Retrospective multicentre study including patients with VEXAS syndrome from the French VEXAS Registry. Episodes of serious infections were described, and their risk factors were analysed using multivariable Cox proportional hazards models. Results Seventy-four patients with 133 serious infections were included. The most common sites of infection were lung (59%), skin (10%) and urinary tract (9%). Microbiological confirmation was obtained in 76%: 52% bacterial, 30% viral, 15% fungal and 3% mycobacterial. Among the pulmonary infections, the main pathogens were SARS-CoV-2 (28%), Legionella pneumophila (21%) and Pneumocystis jirovecii (19%). Sixteen per cent of severe infections occurred without any immunosuppressive treatment and with a daily glucocorticoid dose ≤10 mg. In multivariate analysis, age >75 years (HR (95% CI) 1.81 (1.02 to 3.24)), p.Met41Val mutation (2.29 (1.10 to 5.10)) and arthralgia (2.14 (1.18 to 3.52)) were associated with the risk of serious infections. JAK inhibitors were most associated with serious infections (3.84 (1.89 to 7.81)) compared with biologics and azacitidine. After a median follow-up of 4.4 (2.5–7.7) years, 27 (36%) patients died, including 15 (56%) due to serious infections. Conclusion VEXAS syndrome is associated with a high incidence of serious infections, especially in older patients carrying the p.Met41Val mutation and treated with JAK inhibitors. The high frequency of atypical infections, especially in patients without treatment, may indicate an intrinsic immunodeficiency.
- 9 December 2023
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 83 (3) , 372-381
Serious infections in patients with VEXAS syndrome: data from the French VEXAS registry
Introduction Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is an acquired autoinflammatory monogenic disease with a poor prognosis whose determinants are not well understood. We aimed to describe serious infectious complications and their potential risk factors. Methods Retrospective multicentre study including patients with VEXAS syndrome from the French VEXAS Registry. Episodes of serious infections were described, and their risk factors were analysed using multivariable Cox proportional hazards models. Results Seventy-four patients with 133 serious infections were included. The most common sites of infection were lung (59%), skin (10%) and urinary tract (9%). Microbiological confirmation was obtained in 76%: 52% bacterial, 30% viral, 15% fungal and 3% mycobacterial. Among the pulmonary infections, the main pathogens were SARS-CoV-2 (28%), Legionella pneumophila (21%) and Pneumocystis jirovecii (19%). Sixteen per cent of severe infections occurred without any immunosuppressive treatment and with a daily glucocorticoid dose ≤10 mg. In multivariate analysis, age >75 years (HR (95% CI) 1.81 (1.02 to 3.24)), p.Met41Val mutation (2.29 (1.10 to 5.10)) and arthralgia (2.14 (1.18 to 3.52)) were associated with the risk of serious infections. JAK inhibitors were most associated with serious infections (3.84 (1.89 to 7.81)) compared with biologics and azacitidine. After a median follow-up of 4.4 (2.5–7.7) years, 27 (36%) patients died, including 15 (56%) due to serious infections. Conclusion VEXAS syndrome is associated with a high incidence of serious infections, especially in older patients carrying the p.Met41Val mutation and treated with JAK inhibitors. The high frequency of atypical infections, especially in patients without treatment, may indicate an intrinsic immunodeficiency.
- 14 August 2023
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 117, 140-143
Diagnoses associated with temporal arteritis
- 14 August 2023
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 117, 140-143
Diagnoses associated with temporal arteritis
- 6 August 2022
- Published by Elsevier in Autoimmunity Reviews
- Vol. 21 (10) , 103168
JAK inhibitors and systemic sclerosis: A systematic review of the literature
- 6 August 2022
- Published by Elsevier in Autoimmunity Reviews
- Vol. 21 (10) , 103168
JAK inhibitors and systemic sclerosis: A systematic review of the literature
- 1 March 2022
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 97, 62-68
Interstitial pneumonia with autoimmune features: Evaluation of connective tissue disease incidence during follow-up
- 1 March 2022
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 97, 62-68
Interstitial pneumonia with autoimmune features: Evaluation of connective tissue disease incidence during follow-up